Press release
Basal Cell Carcinoma Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight | AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound, PellePharm, Inc., Medivir, Merck Sharp & Dohme LLC
Basal Cell Carcinoma Market
To Know in detail about the Basal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Basal Cell Carcinoma Market Forecast
https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key facts of the Basal Cell Carcinoma Market Report:
• The Basal Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2024, Verrica Pharmaceuticals administered the final dose to the last participant in the second segment of the Phase II study evaluating VP-315, a novel oncolytic peptide immunotherapy targeting basal cell carcinoma, the most prevalent type of skin cancer. This Phase II trial comprises two parts and is an open-label, multicenter investigation aiming to establish the safety, pharmacokinetics, and effectiveness of the treatment through intratumoral administration in adult individuals with confirmed basal cell carcinoma.
• Skin cancer is the most prevalent cancer in the United States, according to the American Cancer Society (ACS), with basal cell carcinoma (BCC) accounting for the majority of occurrences. According to the ACS, over 3.4 million people in the US receive an estimated 5.4 million diagnoses of basal and squamous cell skin malignancies each year, with BCCs accounting for about 80% of those cases
• The most prevalent type of skin cancer worldwide, according to the European Skin Cancer Foundation, is basal cell carcinoma. About 50 to 80 new cases of basal cell carcinoma are reported annually per 100,000 people in Europe
• The estimated annual incidence of Basal Cell Carcinoma in the United States is 4.3 million, according to information from insurance registries and official statistics
• Key Basal Cell Carcinoma Companies: AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound, PellePharm, Inc., Medivir, Merck Sharp & Dohme LLC, Amarex Clinical Research, Sanofi, Hoffmann-La Roche, Bristol-Myers Squibb, Will-Pharma, Novartis, AiViva BioPharma, Inc., MediWound Ltd, Galderma R&D, Genentech, Inc., Peplin, MEDA Pharma, and others
• Key Basal Cell Carcinoma Therapies: AIV001, STP705, Patidegib, MW005, Patidegib, Remetinostat, Vismodegib, STP705, cemiplimab, ERIVEDGE, Nivolumab, Sinecatechins 10%, LDE225, AIV001, EscharEx, Metvix® cream, Vismodegib, PEP005, Imiquimod, and others
• The Basal Cell Carcinoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Basal Cell Carcinoma pipeline products will significantly revolutionize the Basal Cell Carcinoma market dynamics.
Basal Cell Carcinoma Overview
Basal cell carcinoma (BCC) is the most common form of skin cancer. It arises from the basal cells, which are located in the lowest layer of the epidermis, the outermost layer of the skin. Basal cell carcinoma typically appears as a raised, pearly bump or a pinkish patch of skin. It can also present as a non-healing sore or a shiny growth with blood vessels visible on its surface.
Get a Free sample for the Basal Cell Carcinoma Market Report:
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Basal Cell Carcinoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Basal Cell Carcinoma Epidemiology Segmentation:
The Basal Cell Carcinoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Basal Cell Carcinoma
• Prevalent Cases of Basal Cell Carcinoma by severity
• Gender-specific Prevalence of Basal Cell Carcinoma
• Diagnosed Cases of Episodic and Chronic Basal Cell Carcinoma
Download the report to understand which factors are driving Basal Cell Carcinoma epidemiology trends @ Basal Cell Carcinoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Basal Cell Carcinoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Basal Cell Carcinoma market or expected to get launched during the study period. The analysis covers Basal Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Basal Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Basal Cell Carcinoma Therapies and Key Companies
• AIV001: AiVivA Biopharma
• STP705: Sirnaomics
• Patidegib: Pellepharm/ SolGel Technologies
• MW005: Mediwound
• Patidegib: PellePharm, Inc.
• Remetinostat: Medivir
• Vismodegib: Merck Sharp & Dohme LLC
• STP705: Amarex Clinical Research
• cemiplimab: Sanofi
• ERIVEDGE: Hoffmann-La Roche
• Nivolumab: Bristol-Myers Squibb
• Sinecatechins 10%: Will-Pharma
• LDE225: Novartis
• AIV001: AiViva BioPharma, Inc.
• EscharEx: MediWound Ltd
• Metvix® cream: Galderma R&D
• Vismodegib: Genentech, Inc.
• PEP005: Peplin
• Imiquimod: MEDA Pharma
Discover more about therapies set to grab major Basal Cell Carcinoma market share @ Basal Cell Carcinoma Treatment Market
https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Basal Cell Carcinoma Market Drivers
• Rise in various environmental factors, which leads to more UV exposure and an increasing geriatric population who are more susceptible to skin disease.
Basal Cell Carcinoma Market Barriers
• Constant research and well defined clinical trials may help in identifying potential novel treatments and improve outcomes for basal cell carcinoma patients, potential for premium pricing of emerging therapies by showing an edge over current therapies
Scope of the Basal Cell Carcinoma Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Basal Cell Carcinoma Companies: AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound, PellePharm, Inc., Medivir, Merck Sharp & Dohme LLC, Amarex Clinical Research, Sanofi, Hoffmann-La Roche, Bristol-Myers Squibb, Will-Pharma, Novartis, AiViva BioPharma, Inc., MediWound Ltd, Galderma R&D, Genentech, Inc., Peplin, MEDA Pharma, and others
• Key Basal Cell Carcinoma Therapies: AIV001, STP705, Patidegib, MW005, Patidegib, Remetinostat, Vismodegib, STP705, cemiplimab, ERIVEDGE, Nivolumab, Sinecatechins 10%, LDE225, AIV001, EscharEx, Metvix® cream, Vismodegib, PEP005, Imiquimod, and others
• Basal Cell Carcinoma Therapeutic Assessment: Basal Cell Carcinoma current marketed and Basal Cell Carcinoma emerging therapies
• Basal Cell Carcinoma Market Dynamics: Basal Cell Carcinoma market drivers and Basal Cell Carcinoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Basal Cell Carcinoma Unmet Needs, KOL's views, Analyst's views, Basal Cell Carcinoma Market Access and Reimbursement
To know more about Basal Cell Carcinoma companies working in the treatment market, visit @ Basal Cell Carcinoma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Basal Cell Carcinoma Market Report Introduction
2. Executive Summary for Basal Cell Carcinoma
3. SWOT analysis of Basal Cell Carcinoma
4. Basal Cell Carcinoma Patient Share (%) Overview at a Glance
5. Basal Cell Carcinoma Market Overview at a Glance
6. Basal Cell Carcinoma Disease Background and Overview
7. Basal Cell Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Basal Cell Carcinoma
9. Basal Cell Carcinoma Current Treatment and Medical Practices
10. Basal Cell Carcinoma Unmet Needs
11. Basal Cell Carcinoma Emerging Therapies
12. Basal Cell Carcinoma Market Outlook
13. Country-Wise Basal Cell Carcinoma Market Analysis (2019-2032)
14. Basal Cell Carcinoma Market Access and Reimbursement of Therapies
15. Basal Cell Carcinoma Market Drivers
16. Basal Cell Carcinoma Market Barriers
17. Basal Cell Carcinoma Appendix
18. Basal Cell Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Basal Cell Carcinoma Market Forecast 2032: Epidemiology, FDA Approvals, Therapies, Clinical Trials and Companies by DelveInsight | AiVivA Biopharma, Sirnaomics, Pellepharm/ SolGel Technologies, Mediwound, PellePharm, Inc., Medivir, Merck Sharp & Dohme LLC here
News-ID: 3557067 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for Basal
Basal Cell Carcinoma Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Basal Cell Carcinoma Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The basal cell carcinoma (BCC) treatment market is witnessing significant growth due to the increasing incidence of BCC, which is the most common…
Basal Cell Carcinoma Treatment Market - Industry Trends and Forecast
Latest "Basal Cell Carcinoma Treatment Market" Size, Share & Trends Analysis Research Report 2024 - By Applications (Auto Sales, Employment Opportunities, Rental Properties, Pets, Other), By Types (Featured ads, Normal ad), By Segmentation analysis, Regions and Forecast to 2031. The Global Basal Cell Carcinoma Treatment market Report provides In-depth analysis on the market status of the Basal Cell Carcinoma Treatment Top manufacturers with best facts and figures, meaning, Definition, SWOT…
What is the best treatment for basal cell cancer?
Basal cell carcinoma is most common type of non-melanoma skin cancer and generally referred to as a 'rodent ulcers'. Skin has three main types of cells in the top layer of the skin in which basal cells line the epidermis layers. Basal cells are shed or replaced as new ones grow/form. The carcinoma looks like open sores, red patches, shiny bumps, slightly elevated growth on skin with rolled edges. Basal…
Basal Cell Carcinoma Treatment Market Report Up to 2031
Visiongain has published a new report on Basal Cell Carcinoma Treatment Market Report to 2031. Profiles of Leading Basal Cell Carcinoma Treatment Market players, Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
The global Basal Cell Carcinoma Treatment Market has been growing considerably owing to the rising incidence and prevalence rate of Basal Cell Carcinoma, rising awareness campaigns, and significant investment in the R&D process. Furthermore, the rising healthcare…
Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline : In-depth Analysis, Revi …
The Global Basal Cell Carcinoma (Basal Cell Epithelioma) Market Research Report Forecast 2020-2022: The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Basal Cell Carcinoma (Basal Cell Epithelioma) Market. The report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Basal Cell Carcinoma (Basal Cell Epithelioma) Market. It takes into account the CAGR, value, volume, revenue,…
Basal Cell Carcinoma (Basal Cell Epithelioma) Global Market Research Report 2025
Basal Cell Carcinoma (Basal Cell Epithelioma) Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/basal-cell-carcinoma-basal-cell-epithelioma-market/80990
The report firstly introduced the Basal Cell Carcinoma…
